Dr Phillips brings 30 years of healthcare leadership experience in commercial operations, business strategy, business development and drug development functions
Basel, 13 July, 2022 – Anaveon, a clinical-stage immuno-oncology company, today announces the appointment of Dr Gary Phillips as Chief Business Officer with immediate effect. Dr Phillips has three decades of leadership experience in multiple roles across the healthcare industry, most recently serving as President & CEO of OrphoMed. In his role at Anaveon, Dr Phillips will serve on the executive committee and will shape and oversee Anaveon’s business and corporate development strategy.
“Gary has broad experience in leadership roles and long-standing relationships across the life sciences industry and I am delighted to welcome him to our executive committee,” said Dr Andreas Katopodis, Chief Executive Officer at Anaveon. “He joins us at an exciting time and his experience will be invaluable as we progress our lead program, ANV419, through development in multiple tumor types and expand our pipeline with novel late-preclinical drug candidates.”
“I am excited to join Anaveon at this time, with the unique characteristics of ANV419 pointing to its potential as a transformational therapy for patients with cancer, both as monotherapy and in combination with other therapies,” added Dr Gary Phillips. “I look forward to working with the experienced team and to shaping Anaveon’s business and corporate strategy.”
Dr Gary Phillips has three decades of experience across healthcare. He was President & CEO of OrphoMed from 2018 to 2022. Prior to OrphoMed, Dr Phillips was EVP & Chief Strategy Officer as well as President, Autoimmune & Rare Diseases at Mallinckrodt Pharmaceuticals. He was previously Head of Global Health & Healthcare at the World Economic Forum and has served in senior executive roles at Reckitt Benckiser Pharmaceuticals, Bausch & Lomb, Merck Serono, Novartis, and Wyeth. He earned a BA in Biochemistry summa cum laude from the University of Pennsylvania’s College of Arts & Sciences, an MBA from its Wharton School, and an MD Alpha Omega Alpha from its School of Medicine. Dr Phillips practiced as a U.S. Navy general medical officer. He currently serves as Chairman of the Board of Nanobiotix as well as a Director on the Boards of Aldeyra Therapeutics and Rheon Medical SA.
ENDS
Enquiries
JW Communications
Julia Wilson
Tel: +44 (0)7818 430877
Email: julia.wilson@anaveon.com
About Anaveon
Anaveon is a clinical-stage biopharmaceutical company, based in Switzerland, that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to cancer patients. Our vision is to develop novel immune therapies benefiting patients suffering from a wide variety of diseases with immune pathology. For further information please visit the Company’s website at: www.anaveon.com.
About ANV419
ANV419 is a powerful and selective interleukin-2 (IL-2) agonist to target cancer. In the body, human IL-2 stimulates a type of immune cell, called a T-cell, to multiply and become activated. Activated T-cells are able to attack tumors and, consistent with this approach, human IL-2 is already approved as a therapeutic for the treatment of metastatic melanoma and renal cancer; however, due to lack of specificity, human IL-2 has severe, dose-limiting side effects and a short half-life that requires frequent infusions. ANV419, is designed to preferentially signal through the IL-2 beta/gamma receptor and therefore overcome known challenges of human IL-2. This novel type of therapeutic, if approved, could potentially have a wide utility in oncology, including in combination with cell therapies, vaccines, checkpoint inhibitors and radiotherapy.